Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Paclitaxel 22Carboplatin 18liposomal doxorubicin 14Bevacizumab 9Topotecan 8Docetaxel 8Gemcitabine 7Cisplatin 7rucaparib 6pembrolizumab 6mirvetuximab soravtansine 5Cyclophosphamide 5Taxes 4Albumin-Bound Paclitaxel 4sargramostim 3ixabepilone 3Cytoreduction Surgical Procedures 3CCV-AV protocol 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2pazopanib 2olaparib 2fludarabine phosphate 2fludarabine 2denileukin diftitox 2cediranib 2catumaxomab 2belinostat 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ovarian Epithelial × Receptor Protein-Tyrosine Kinases × Clear all
NCT00373217 2022-09-21

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

University of Virginia

Phase 2 Terminated
6 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡